New ICD-10-PCS Codes in

556 codes were added to the 2021 ICD-10-PCS code set, effective October 1, 2020.

Displaying codes 501-556 of 556:

  • DT12B6Z Low Dose Rate (LDR) Brachytherapy of Bladder using Cesium 131 (Cs-131)
  • DT13B6Z Low Dose Rate (LDR) Brachytherapy of Urethra using Cesium 131 (Cs-131)
  • DU10B6Z Low Dose Rate (LDR) Brachytherapy of Ovary using Cesium 131 (Cs-131)
  • DU11B6Z Low Dose Rate (LDR) Brachytherapy of Cervix using Cesium 131 (Cs-131)
  • DU12B6Z Low Dose Rate (LDR) Brachytherapy of Uterus using Cesium 131 (Cs-131)
  • DV10B6Z Low Dose Rate (LDR) Brachytherapy of Prostate using Cesium 131 (Cs-131)
  • DV11B6Z Low Dose Rate (LDR) Brachytherapy of Testis using Cesium 131 (Cs-131)
  • DW11B6Z Low Dose Rate (LDR) Brachytherapy of Head and Neck using Cesium 131 (Cs-131)
  • DW12B6Z Low Dose Rate (LDR) Brachytherapy of Chest using Cesium 131 (Cs-131)
  • DW13B6Z Low Dose Rate (LDR) Brachytherapy of Abdomen using Cesium 131 (Cs-131)
  • DW16B6Z Low Dose Rate (LDR) Brachytherapy of Pelvic Region using Cesium 131 (Cs-131)
  • X2AH336 Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Right Common Carotid Artery, Percutaneous Approach, New Technology Group 6
  • X2AJ336 Cerebral Embolic Filtration, Extracorporeal Flow Reversal Circuit from Left Common Carotid Artery, Percutaneous Approach, New Technology Group 6
  • XNU0356 Supplement Lumbar Vertebra with Mechanically Expandable (Paired) Synthetic Substitute, Percutaneous Approach, New Technology Group 6
  • XNU4356 Supplement Thoracic Vertebra with Mechanically Expandable (Paired) Synthetic Substitute, Percutaneous Approach, New Technology Group 6
  • XW013F5 Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW03306 Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03326 Introduction of Nerinitide into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03336 Introduction of Durvalumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03366 Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03396 Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033A6 Introduction of Cefiderocol Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033B6 Introduction of Omadacycline Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033C6 Introduction of Eculizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033D6 Introduction of Atezolizumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW033E5 Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033F5 Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033G5 Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW033H5 Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW04306 Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04326 Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04336 Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04366 Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043A6 Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043B6 Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043C6 Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043D6 Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW097M5 Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5
  • XW0DX66 Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
  • XW0DXF5 Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0G886 Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
  • XW0H886 Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6
  • XW0Q316 Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6
  • XW13325 Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5
  • XW14325 Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW23346 Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW23376 Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW24346 Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
  • XW24376 Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6
  • XXE5XN6 Measurement of Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, New Technology Group 6
  • XXEBXQ6 Measurement of Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, New Technology Group 6